Primers used to sequence the CLDN6, CLDN9 and OCLN genes.

<p>Primers used to sequence the CLDN6, CLDN9 and OCLN genes.</p

Primers used to sequence the SCARB1 gene.

<p>Primers used to sequence the SCARB1 gene.</p

Variants of HCV entry factors found in HIV-infected, HCV-uninfected patients but not in HIV/HCV-coinfected controls.

<p>^a Database single nucleotide polymorphism. ^b 1000 Genomes database. ^c refSNP reference identification number of single nucleotide polymorphism. ^d Not attributed. ^e Minor allele frequency. ^f Intravenous drug users.</p

Schematic representation of of CLDN6, CLDN9, OCLN and SCARB1 genes.

<p>Exons are represented by numbered gray rectangles and introns or non coding regions by double blue lines. Positions of primers pairs used for direct genomic sequencing are shown. Reference sequences of the transcripts are NM_021195.4 (CLDN6), NM_020982.3 (CLDN9), NM_002538.3 (OCLN) and NM_005505.4 (SCARB1). The numbering starts at the first base of the initiation codon ATG, and stops at the first base of the termination codon of the corresponding transcripts. The sequences of corresponding primers are shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142698#pone.0142698.t001" target="_blank">Table 1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142698#pone.0142698.t002" target="_blank">Table 2</a>. F: Forward primer, R: Reverse primer, LR: Long Range PCR primer. SNPs identified by direct genomic sequencing are indicated, in red SNPs specific of the case population HIV+ HCV-.</p

Risk factors for atazanavir-associated urolithiasis, univariate analysis.

<p>Risk factors for atazanavir-associated urolithiasis, univariate analysis.</p

Baseline characteristics of HIV-infected patients with atazanavir-associated urolithiasis and controls.

<p>Baseline characteristics of HIV-infected patients with atazanavir-associated urolithiasis and controls.</p

Risk factors for atazanavir-associated urolithiasis, multivariate analysis.

<p>Risk factors for atazanavir-associated urolithiasis, multivariate analysis.</p

Clinical presentation and outcome of 30 patients with ATV-associated urolithiasis.

<p>Clinical presentation and outcome of 30 patients with ATV-associated urolithiasis.</p

Treatment at admission.

Novel antibiotics: ceftolozan /tazobactam, ceftazidime /avibactam.</p

Univariate analysis of the association between the measured variables and death or ICU admission.

Univariate analysis of the association between the measured variables and death or ICU admission.</p